Compare Natera Inc. Common Stock (NTRA) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Schwab US Large Cap Growth ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Schwab US Large Cap Growth ETF trades at $35.61 (market cap $65.41B). The key difference: Natera Inc. Common Stock and Schwab US Large Cap Growth ETF are close in size by market cap, and Schwab US Large Cap Growth ETF is more actively traded (6,607,358 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Schwab US Large Cap Growth ETF for 52 Days on average.
| NTRA | SCHG | |
|---|---|---|
Market Cap | $57.03B | $65.41B |
Volume | 1,131,157 | 6,607,358 |
Sector | Health | Sector/Thematic |
52-Week High | $425.64 | $36.93 |
52-Week Low | $179.42 | $28.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SCHG trades at $36.59 with no daily change, showing stability amid a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong institutional interest despite a recent 20% position reduction by Corient Private Wealth. Recent news highlights SCHG's competitive positioning among large-cap growth ETFs with its 0.03% expense ratio and concentration in megacap technology stocks.
The outlook remains positive given SCHG's historical outperformance versus the S&P 500, though concentration risk in top holdings and potential valuation concerns warrant monitoring. Growth investors may benefit from the ETF's low-cost exposure to leading US companies, but should be aware of narrowing performance gaps with broader market alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
